#ASCO2017 Consensus Molecular Subgroups (CMS) of Colorectal Cancer (CRC) and 1st Line Efficacy of FOLFIRI Plus Cetuximab or Bevacizumab: Analysis of the FIRE-3 (AIO KRK 0306) Study